Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.

Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A, Greco A, Logroscino G.

Biomed Res Int. 2016;2016:3245935. doi: 10.1155/2016/3245935. Epub 2016 Jun 26. Review.

2.

The Ever-Changing Morphology of Hippocampal Granule Neurons in Physiology and Pathology.

Llorens-Martín M, Rábano A, Ávila J.

Front Neurosci. 2016 Jan 19;9:526. doi: 10.3389/fnins.2015.00526. eCollection 2015.

3.

Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits.

Jiao SS, Yao XQ, Liu YH, Wang QH, Zeng F, Lu JJ, Liu J, Zhu C, Shen LL, Liu CH, Wang YR, Zeng GH, Parikh A, Chen J, Liang CR, Xiang Y, Bu XL, Deng J, Li J, Xu J, Zeng YQ, Xu X, Xu HW, Zhong JH, Zhou HD, Zhou XF, Wang YJ.

Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5225-30. doi: 10.1073/pnas.1422998112. Epub 2015 Apr 6.

4.

Cyclin-Dependent kinase 5 targeting prevents β-Amyloid aggregation involving glycogen synthase kinase 3β and phosphatases.

Castro-Alvarez JF, Uribe-Arias A, Cardona-Gómez GP.

J Neurosci Res. 2015 Aug;93(8):1258-66. doi: 10.1002/jnr.23576. Epub 2015 Feb 24.

5.

CDK5 activator protein p25 preferentially binds and activates GSK3β.

Chow HM, Guo D, Zhou JC, Zhang GY, Li HF, Herrup K, Zhang J.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4887-95. doi: 10.1073/pnas.1402627111. Epub 2014 Oct 20. Erratum in: Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):E3313.

6.
7.

Cyclin-dependent kinase 5, a node protein in diminished tauopathy: a systems biology approach.

Castro-Alvarez JF, Uribe-Arias SA, Mejía-Raigosa D, Cardona-Gómez GP.

Front Aging Neurosci. 2014 Sep 1;6:232. doi: 10.3389/fnagi.2014.00232. eCollection 2014. Review.

8.

Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials.

Jia Q, Deng Y, Qing H.

Biomed Res Int. 2014;2014:837157. doi: 10.1155/2014/837157. Epub 2014 Jul 17. Review.

9.

Physiological and pathological phosphorylation of tau by Cdk5.

Kimura T, Ishiguro K, Hisanaga S.

Front Mol Neurosci. 2014 Jul 15;7:65. doi: 10.3389/fnmol.2014.00065. eCollection 2014. Review.

10.

Neuregulin1-β decreases IL-1β-induced neutrophil adhesion to human brain microvascular endothelial cells.

Wu L, Walas S, Leung W, Sykes DB, Wu J, Lo EH, Lok J.

Transl Stroke Res. 2015 Apr;6(2):116-24. doi: 10.1007/s12975-014-0347-9. Epub 2014 May 28.

11.

Protein phosphorylation in neurodegeneration: friend or foe?

Tenreiro S, Eckermann K, Outeiro TF.

Front Mol Neurosci. 2014 May 13;7:42. doi: 10.3389/fnmol.2014.00042. eCollection 2014. Review.

12.

Generation of the Cdk5 activator p25 is a memory mechanism that is affected in early Alzheimer's disease.

Giese KP.

Front Mol Neurosci. 2014 May 1;7:36. doi: 10.3389/fnmol.2014.00036. eCollection 2014. Review.

13.

The Beta-amyloid protein of Alzheimer's disease: communication breakdown by modifying the neuronal cytoskeleton.

Mokhtar SH, Bakhuraysah MM, Cram DS, Petratos S.

Int J Alzheimers Dis. 2013;2013:910502. doi: 10.1155/2013/910502. Epub 2013 Dec 12. Review.

14.

Recent developments of protein kinase inhibitors as potential AD therapeutics.

Tell V, Hilgeroth A.

Front Cell Neurosci. 2013 Nov 19;7:189. doi: 10.3389/fncel.2013.00189. Review.

15.

Neuroprotective Sirtuin ratio reversed by ApoE4.

Theendakara V, Patent A, Peters Libeu CA, Philpot B, Flores S, Descamps O, Poksay KS, Zhang Q, Cailing G, Hart M, John V, Rao RV, Bredesen DE.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18303-8. doi: 10.1073/pnas.1314145110. Epub 2013 Oct 21.

16.

The role of Cdk5 in neuroendocrine thyroid cancer.

Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V, Meyer D, Guo A, Gundara J, Mettlach G, Richer E, Guevara JA, Ning L, Gupta A, Hao G, Tsai LH, Sun X, Antich P, Sidhu S, Robinson BG, Chen H, Nwariaku FE, Pfragner R, Richardson JA, Bibb JA.

Cancer Cell. 2013 Oct 14;24(4):499-511. doi: 10.1016/j.ccr.2013.08.027.

17.

An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease.

Cavallini A, Brewerton S, Bell A, Sargent S, Glover S, Hardy C, Moore R, Calley J, Ramachandran D, Poidinger M, Karran E, Davies P, Hutton M, Szekeres P, Bose S.

J Biol Chem. 2013 Aug 9;288(32):23331-47. doi: 10.1074/jbc.M113.463984. Epub 2013 Jun 24.

18.

Astroglial PTEN Loss Disrupts Neuronal Lamination by Dysregulating Radial Glia-guided Neuronal Migration.

Wen Y, Li W, Choudhury GR, He R, Yang T, Liu R, Jin K, Yang SH.

Aging Dis. 2013 May 6;4(3):113-26. Print 2013 Jun.

19.

Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Bartzokis G.

Neuropharmacology. 2012 Jun;62(7):2137-53. doi: 10.1016/j.neuropharm.2012.01.015. Epub 2012 Jan 28. Review.

20.

Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets.

Lee VM, Brunden KR, Hutton M, Trojanowski JQ.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006437. doi: 10.1101/cshperspect.a006437. Review.

Supplemental Content

Support Center